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Proteases play an important and critical role in the physiological process of wound repair. However, exces-
sive and unregulated release of proteolytic enzymes (e.g., elastase) mediates abnormal degradation of
healthy tissues, which leads to inﬂammatory disorders such as chronic wounds. Thus, it is of therapeutic
interest to develop novel synthetic inhibitor-peptides of elastase, which can restore the balance between
the free enzyme and the endogenous inhibitors in chronic wounds. In previous works, we have reported
two different drug delivery systems to release novel elastase inhibitors to the wound site. In both systems
synthetic peptides (KRCCPDTCGIKCL-Pep4 andKRMMPDTMGIKML-Pep4M)basedon theprimary structure
of the endogenous elastase inhibitor, secretory leucocyte protease inhibitor, were used as active material.
Phosphorylation of the reported peptides prompts signiﬁcant structural differences, which reﬂects in dis-
tinct inhibitory capacity towards elastase. These structural modiﬁcations were prompted by electrostatic
interactions and hydrogen bonds established from the peptide phosphoresidue. The current studywas also
extended to another synthetic peptide (WCTASVPPQCY-PepBBI) that is basedon the reactive loopof another
elastase inhibitor, the Bowmen-Birk inhibitor. PepBBI, phosphorylated and non-phosphorylated, displays
similar behaviour to Pep4 and Pep4M. The structural modiﬁcations reported herein were evaluated by
two-dimensional nuclear magnetic resonance and molecular modelling approaches.
 2013 Elsevier Ltd. All rights reserved.1. Introduction characteristic of chronic wounds results in exuberant response ofNormal wound healing is a controlled balance between repair
processes that lead to new tissue formation and destructive pro-
cesses, which are essential to remove damaged tissue [1,2]. The
perfect control of the biological processes involved in healing leads
to normal wound repair. However, any alteration in these physio-
logical processes may lead to a non-healing state and the formation
of a chronic wound [1]. Chronic wounds fail to progress through
the normal stages of healing and therefore enter a state of patho-
logic inﬂammation [2,3]. The prolonged inﬂammatory phaseneutrophils [4]. Neutrophils invade the inﬂammatory sites and
their massive accumulation at the inﬂammation site mediates
the release of high amounts of proteases (concentrations reaching
millimolar range) and free radical generating enzymes that become
deleterious to the healing process [4–7]. The proteolytic environ-
ment of the wound resulting from high neutrophil concentrations
is a combination of cationic serine proteases (e.g., human neutro-
phil elastase (HNE)) and matrix metalloproteinases (e.g. collage-
nase MMP-8 and gelatinase MMP-9) [4,6]. These two families of
proteases, when at normal levels, augment wound healing. How-
ever, at high levels are associated with the degradation of impor-
tant growth factors and major proteins of the extracellular
matrix necessary for wound healing. Among the proteases released
from neutrophils, human neutrophil elastase (HNE) is capable of
cleaving tissue proteins such as elastin, which plays a major func-
tion in the arteries, skin and ligaments, collagen (Types I–V, IX and
XI), ﬁbrin, ﬁbronectin, cartilage, proteoglycans, and cytokines
[5,8,9]. Elastase action is modulated by multiple endogenous inhib-
itors, such as a1-protease inhibitor, secretory leucocyte protease
inhibitor (SLPI) and elaﬁn. Still, under pathological conditions the
oxidative inactivation of these natural protease inhibitors takes
Fig. 1. Secretory leukocyte protease inhibitor (SLPI) primary structure. Identiﬁcation of Pep4 sequence in SLPI structure (in grey).
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chronic inﬂammation, the imbalance is in favour of proteases,
which widely overwhelm the inhibitory capacity of the endoge-
nous proteinaceous inhibitors [5]. To reverse this protease-antipro-
tease imbalance and reinforce the elastase inhibitor’s activity,
different types of inhibitors and inhibitor formulations have been
developed for wound dressings therapeutic applications. The de-
sign of synthetic low molecular weight, peptide-based [14–16] or
non-peptide-based [17–19], elastase inhibitors has received con-
siderable attention due to their potential therapeutic usefulness.
The delivery of inhibitors or other active materials to the wound
medium, promoted by wound dressings, can be accomplished by
two different approaches: (i) the sequestration of elastase directly
from the wound environment, with further protease inactivation
or (ii) the direct release of the protease inhibitor into the wound
medium, to further control the elastase levels in chronic non-heal-
ing wounds [4]. In previous studies [20,21], we have reported two
different drug delivery systems, based on both wound dressing
mechanisms described herein, to deliver novel elastase peptidic
inhibitors to wound environment. The peptide sequence of these
inhibitors, KRCCPDTCGIKCL (Pep4) and KRMMPDTMGIKML
(Pep4M) [20], was selected from an endogenous elastase inhibitor,
secretory leucocyte protease inhibitor (SLPI, Fig. 1). Pep4M is a
mutation of Pep4 sequence, having replaced all cysteine residues
by methionine residues. Both peptides revealed differential inhib-
itory activity towards elastase (porcine pancreatic elastase, PPE)
when a speciﬁc residue (threonine, in this case) is in the phosphor-
ylated and non-phosphorylated form [20]. The structure of pep-
tides Pep4 and Pep4M and the inﬂuence of this posttranslational
modiﬁcation on their structure were evaluated herein by two-
dimensional NMR and molecular modelling studies. Additionally,
these studies were also extended to another elastase inhibitor-
peptide, PepBBI (WCTASVPPQCY), a synthetic peptide derived from
the Bowman-Birk Inhibitor reactive loop [14,22–24], in order to
establish a comparison between PepBBI and the previous peptides.
Similarly to Pep4 and Pep4M, for PepBBI a distinct inhibitory
behaviour was also observed relatively to elastase for the phos-
phorylated and non-phosphorylated version of the peptide
(unpublished data), which is reﬂected in the structural conforma-
tions adopted by the peptide in solution.2. Materials and methods
2.1. NMR experiments
2.1.1. NMR sample preparation
The elastase inhibitor-peptides Pep4 (KRCCPDTCGIKCL), Pep4M
(KRMMPDTMGIKML) and PepBBI (WCTASVPPQCY) used in this
study were custom-made by JPT Peptide Technologies GmbH (Ber-
lin, DE) [25].The NMR analysis of the tridecameric peptides (Pep4 and
Pep4M) [20] and undecameric peptide (PepBBI) [14,24] was per-
formed in aqueous solution (90% H2O/10% 2H2O) at 283 K to slow
down molecular tumbling and at pH 3.0 to minimise the rate of ex-
change of NH protons with the solvent. Working at pH below 7 is
standard for structural determination of proteins by NMR. The
NMR samples were prepared at a concentration of approximately
4 mg/mL using water (with 10% D2O) as solvent, for signal lock.
2.1.2. NMR spectra acquisition and analysis
NMR data were acquired on a Bruker Avance II+ spectrometer
operating at proton frequency of 500 MHz (Fig. 2). Two-dimensional
homonuclear (2D)NMRexperimentswere performed: a 1H-Double-
quantumﬁltered COSY [26]with 2k points covering a spectralwidth
of 6 kHz and512 increments in the indirect dimension; a TOCSY [27]
with 60 ms of spin-lock time and a 2k points covering a spectral
width of 6 kHz and 512 increments in the indirect dimension and
a NOESY [28,29] with 300 ms mixing time and 2k points covering
a spectral width of 6 kHz and 1k increments in the indirect dimen-
sion.NOEbuildupexperimentswere performed to conﬁrmthatwith
this mixing time the condition of initial buildup is still valid. In all
cases suppression of the solvent signal was obtained using aWater-
gate sequence with gradients. Additional NOESY experiments were
performed using 300 ms of mixing time in a Bruker Avance III NMR
spectrometer, operating at 800 MHz using a QXI probehead. 2k
points covering a spectral width of 10.4 kHz were measured for 1k
increments in the indirect dimension, to obtain further structural
constrains. The solvent signal was suppressed using excitation
sculpting with gradients. The Topspin software was used to process
the data. All experimentswere zero ﬁlled to duplicate the number of
points in both dimensions. NOESY and TOCSY data were multiplied
in both dimensions by a cosine squaredwindowing function prior to
Fourier transform. COSYdataweremultiplied in bothdimensions by
a sine squared function prior to Fourier transform. Baseline correc-
tion was made following Fourier transformation using a 5th degree
polynomial function. Peak lists of the three aforementioned2Dspec-
tra were generated by interactive peak picking with further auto-
matic integration of the peak volumes in the SPARKY software [30]
(Table SI1–3). Peak assignments in COSY, TOCSY and NOESY spectra
were performed using the sequential assignmentmethod described
byWüthrich [31,32]. The chemical shifts and volumes of the NOESY
crosspeakswere converted into XEASY format and input in the CYA-
NA 2.0 program for structure calculations and analysis.
2.1.3. Structure determination
Assignments of ambiguous NOESY cross peaks were obtained
by using the module CANDID in the program CYANA [33]. A total
of 100 conformers were generated by CYANA and the 20 conform-
ers with lowest target function were used to represent the 3D NMR
structural bundle (Table 1). The quality of the structures was
Fig. 2. Pep4 (a), Pep4M (b) and PepBBI (c) inhibitor-peptides proton NMR spectra
(1H NMR). These spectra were acquired in a 500 MHz Bruker NMR spectrometer.
Table 1
Characterisation of the 20 energy-reﬁned CYANA conformers representing the NMR
structures of Pep4, Pep4M and PepBBI.
Parameters Pep4a Pep4M PepBBIa
Restrains used in the structure calculations
Number of distance restrains
Intra (|i  j| = 0) 81 105 72
(61.8%) (65.6%) (66.1%)
Short-range (|i  j| = 1) 50 49 36
(38.2%) (30.6%) (33.0%)
Medium-range (1<|i  j| 6 4) 0 6 1
(0%) (3.8%) (0.9%)
Long-range (|i  j| > 4) 0 0 0
Total 131 160 109
(100%) (100%) (100%)
Number of torsion angle restrains
U 0 0 0
Final CYANA structures
Target function (Åb) 0.13 ± 0.02 0.038 ± 0.008 0.04 ± 0.02
Structural statistics
Atomic root mean square deviation (RMSD) from the mean structure (Å)
Backbone atoms (N, Ca, C, O) 2.3 ± 0.5 1.8 ± 0.6 2.0 ± 0.6
All heavy atoms 3.4 ± 0.7 2.9 ± 0.7 3.4 ± 0.7
Ramachandran analysisb
Most favoured regions (%) 63.9 50.0 43.6
Additional allowed regions (%) 28.9 48.9 50.7
Generously allowed regions (%) 7.2 1.1 5.7
Disallowed regions (%) 0 0 0
a Peptide structures generated without constrains on disulphide bridges.
b Structure quality was analysed by using PROCHECK [34].
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PROCHECK-NMR program [34,35]. The ﬁnal structures were dis-
played and analysed on MOLMOL [36] and PyMOL [37] software,
respectively.2.2. Molecular docking assays
Molecular docking studies were performed using the X-ray
structure of PPE with PDB code 1B0E with Autodock/Vina [38].
The grid for the ligand conformational search calculations was
placed with its centre located at the PPE binding site. The docking
grid size was 32  59  27 grid points with 1.0 Å spacing. Confor-
mational search was done using the Iterative Local Search algo-
rithm and 10 conformational poses with the lowest binding free
energy were recorded. The peptides were modelled as fully ﬂexible
except for the main-chain peptide amide bonds. Peptides were
docked in their phosphorylated and non-phosphorylated form:
Pep4 and Pep4(P) phosphorylated on Thr7; Pep4M and Pep4M(P)
phosphorylated on Thr7; PepBBI and PepBBI(P) phosphorylated
on Thr3, Ser5 and both residues. The best conformations with the
lowest binding free energy were selected and analysed.3. Results and discussion
3.1. NMR studies
The NMR structure of the peptides, Pep4, Pep4M and PepBBI,
were determined by two-dimensional homonuclear experiments,
COSY and TOCSY, for spin-system assignment and NOESY experi-
ments for sequential assignment of the spin-systems and distance
restraints (see materials and methods section, Table 1 and Fig. 3).
Data were collected at pH below 7 to minimise the proton ex-
change of the NH groups with the solvent. Preliminary data col-
lected at 500 MHz showed no signiﬁcant differences in the
intensity or number of NOESY cross peaks between pH 7 and 3
in the aliphatic region of the spectrum. This is the region where
the amino acid side chains display signals and where contacts be-
tween amino-acids resulting from different structures should be
revealed. At lower pH the NH region has better spectral charac-
teristics and since only the aspartate side chain of Pep4 and
Pep4M is expected to titrate in this pH range, a low pH was se-
lected for data collection. These peptides have a size that places
them near the condition where the correlation time is close to
the reciprocal of the Larmor frequency and NOE effect is elimi-
nated. To minimise this effect, the experimental temperature
was reduced to 283 K, which led to the observation of clear in-
tra-residue cross-peaks. In this context the low abundance of
medium range, and total lack of long-range cross peaks discussed
below are clear indications of substantial conformational mobility
of these peptides in solution. This experimental observation
agrees with the predictions of DisEMBL(1.5) computational tool
[39] that indicate a large probability of these peptides being dis-
ordered. NOESY data were sufﬁcient to observe proton–proton
NOEs between the amide proton of one residue and the a-proton
of the preceding residue, for all residues in these three peptides
(Fig. 3). In Pep4 NOESY spectrum, no long or even medium range
NOE interactions occur, only short-range interactions, such as
HN–HN, Ha–HN, Hb–HN, were observed.
Fig. 3. Distribution of the NOE connectivities between residues of Pep 4 (KRCCPDTCGIKCL), Pep4M (KRMMPDTMGIKML) and PepBBI (WCTASVPPQCY). The vertical labels
indicate the sequential NOE connectivities and the horizontal label the amino acid sequence of each peptide. Sequential connectivities dNN, daN and dbN manifested by
strong NOESY cross peaks are indicated by thick bands, those observed as medium NOEs are displayed by a line connecting the two related residues. These images were
generated using the CYANA software [33].
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spectrum revealed the existence of medium range NOE connectiv-
ities, between Hai–NHi+2 protons, for Pro5–Thr7, Asp6–Met8,
Met8–Ile10.
PepBBI, also shows medium range NOEs, in this case between
Hbi–NHi+2 protons for Pro8–Cys10, although this data is not shown
in Fig. 3 (see Table 1). In PepBBI, as for the other two peptides, no
long range NOEs were found.
These data allow us to conclude that Pep4M has a lower degree
of conformational ﬂexibility in solution than Pep4 and PepBBI,
which leads to the observation of more medium range distanceFig. 4. Comparison of three-dimension structures obtain by 2D-NMR for Pep4,
Pep4M and PepBBI. Bundles of the 20 energy-minimised conformers were used to
represent the NMR structure of the inhibitor-peptides: Pep4 (a); Pep4M (b) and
PepBBI (c). Figures a–c were prepared by using the program MOLMOL [36] and
PyMOL [37].restraints. Data reported in Table 1 corroborate the previous state-
ments. In the NOESY spectra of these three peptides 62–66% corre-
sponds to intra-residue interactions, 31–38% to short-range
interactions and Pep4M and PepBBI shown almost 4% and 1% of
medium-range interactions, respectively.
The ﬁnal set of 20 structures for Pep4M has a mean global back-
bone R.M.S.D. of 1.8 ± 0.6 Å (Table 1) slightly lower than those ob-
tained for Pep4 and PepBBI, 2.3 ± 0.5 and 2.0 ± 0.6 Å, respectively.
These RMSD values are well in line with values reported in the lit-
erature for peptides of similar size [40,41]. The ﬁnal Pep4M and
PepBBI families (after restrained energy minimisation) have an
average total target function of 0.038 ± 0.008 and 0.04 ± 0.02 Å2
(CYANA units), respectively, while the corresponding value for
Pep4 is 0.13 ± 0.02 Å2. Low target function values have been
achieved for the conformer families of these peptides, although
for Pep4 this value is almost ten times higher than those observed
for the other peptides. This might be due to the fact that no med-
ium range connectivities were observed in the NOESY spectrum of
Pep4, reﬂecting a higher degree of conformational ﬂexibility in the
bundle of 20 lowest energy conformers.
The Ramachandran plots obtained for the geometry validation
show that 92.8%, 98.9% and 94.3% of the residues of Pep4, Pep4M
and PepBBI, respectively, are in the most favoured and allowed re-
gions (Table 1). None of the structures have residues in the disal-
lowed region.3.1.1. Peptides three dimension structure comparison
The backbone of Pep4M and PepBBI is well deﬁned and con-
served along the 13 and 11 amino acid residues, respectively (withFig. 5. Structural comparison of Pep4 (red structure) and Pep4M (blue structure).
The calculated 20 conformers of Pep4 are superimposed with the conformers of
Pep4M. (For interpretation of the references to colour in this ﬁgure legend, the
reader is referred to the web version of this article.)
Fig. 6. Backbone alignment of the 20 energy-reﬁned CYANA conformers of PepBBI with Pep4 (a) and PepBBI with Pep4M (b). The bundle of the 20 conformers of Pep4, Pep4M
and PepBBI are shown in red, blue and green, respectively. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this
article.)
Fig. 7. Overlay of the backbone atoms of PepBBI for the ﬁnal 20 structures generated by CYANA. Comparison of the 20 conformers obtained for PepBBI (WCTASVPPQCY, green
structures) with the structure of another elastase inhibitor-peptide of the same family (NleCTASIPPQCY, PDB ID: 1HD9, grey structure). (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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behaviour was not observed for the other peptide, Pep4 (Fig. 4a), in
which only 14 of the 20 energy-minimised conformers have the
backbone completely superimposed.
The comparison of Pep4 and Pep4M ﬁnal structures reveal sev-
eral structural differences. These peptides have the same primary
structure, although with the mutation of four cysteine residues
by four methionine residues. The presence of methionine residues,
which has a longer side chain, induces steric hindrance that is re-
ﬂected in the observed structural changes. This structural change
inputs a considerable difference in the three dimensional (3D)
structures of these peptides (Fig. 5a and b). Fig. 5 shows the align-
ment of the bundles of 20 conformers obtained for both peptides.
In the alignment of Pep4 to Pep4M ﬁnal conformers, it is possible
to observe that Pep4 structure (red structure) seems to be shifted
right comparatively to Pep4M (blue structure).
Comparing the 20 energy reﬁned conformers obtained for Pep4
and PepBBI (Fig. 6a), it is thus possible to state that Pep4 only
aligns with PepBBI in three residues, Pro5, Asp6 and Thr7 with
Pro7, Pro8 and Gln9, respectively. Even so, few of the 20 conformers
obtained for both peptides show this alignment. Therefore, poor
alignment was observed between peptides Pep4 and PepBBI.
The overlay of the backbone atoms of Pep4M and PepBBI for the
ﬁnal 20 structures generated by CYANA (Fig. 6b), revealed the
alignment of seven amino acid residues of these peptides, Met3–
Gly9 with Ser5–Tyr11, respectively. In this case, a good alignment
between Pep4M and PepBBI was achieved comparatively to Pep4
and PepBBI superposition.
Fig. 7 shows a comparison of PepBBI (WCTASVPPQCY) bundle of
20 conformers with the structure of another peptide from the samefamily (NleCTASIPPQCY, PDB ID:1HD9) [23]. These undecameric
peptides possess the same primary structure, with only two muta-
tions in the ﬁrst and in the sixth amino acid residue (W? Nle and
V? I). According to literature [14,24], these small modiﬁcations in
the PepBBI structure induces considerable enhancement in the
inhibitor constant (Ki) values (Ki decreases an order of magnitude).
The amino acid sequence of these peptides was designed based on
the reactive-site loop of Bowman-Birk inhibitor (BBI), a protease
inhibitor protein. The Bowman-Birk inhibitor interacts with serine
proteases, such as elastase, in an extended or ‘‘canonical’’ loop
[14,24]. This loop, is frequently constrained by the presence of
disulphide bridges and/or extensive hydrogen-bonding networks
[14]. Peptide NleCTASIPPQCY is found to retain essentially the
same three-dimension arrangement of both backbone and side
chains as observed in BBI complete protein (structure obtained at
pH 3.8). Nevertheless, PepBBI (WCTASVPPQCY) does not retain
the loop shape characteristic of the Bowman-Birk inhibitor
(Fig. 7). In PepBBI, no constrains were observed due to disulphide
bridges and therefore instead of a ‘‘canonical’’ loop a ‘‘W’’ shape
was attained (structure obtained at pH 3.0).
3.2. Molecular modelling studies
The posttranslational modiﬁcation (phosphorylation) of these
tridecameric and undecameric peptides induced a signiﬁcant de-
crease in their inhibitory activity towards elastase. Nevertheless,
this effect was more accentuated in the peptides Pep4 and Pep4M
[20] than in peptide PepBBI (unpublished data). Consequently, this
fact is reﬂected in the values of binding free energy (Table 2) for
the interactions enzyme-peptide, in the phosphorylated and
Table 2
Summary of the binding free energies involved in the interaction of the non-
phosphorylated and phosphorylated peptides (Pep4, Pep4M and PepBBI) with
elastase.
Peptides DG (kcal/mol)
Non-phosphorylated Phosphorylated [Phos-(Non-Phos)]
Pep4 6.0 5.2 (Thr) 0.8
Pep4M 5.8 4.8 (Thr) 1.0
PepBBI 7.0 7.1 (Ser) 0.1
6.8 (Thr) 0.2
7.4 (Ser, Thr) 0.4
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ergy differences were achieved (1 kcal/mol) comparatively to
PepBBI (lower than 0.2).
To evaluate the structural modiﬁcations that prompted such
alteration on the inhibitory capacity of these peptides relatively
to elastase (PPE), a combined study involving two dimensional
NMR studies and molecular docking simulations was performed
for the three peptides involved in this study. Therefore, the 20 en-
ergy-minimised conformers obtained by 2D-NMR for Pep4, Pep4M
and PepBBI (shown in previous section), were used to establish
interactions between these peptides and active centre of the serine
protease elastase. Rigid docking experiments were performed using
the NMR energy-minimised structures, however, as expected, the
solution structure of the three peptides by NMR did not allow an
appropriate interaction with the active centre of the enzyme. This
is justiﬁed by the lack of peptide conformational freedom to adaptFig. 8. Docking complexes with the highest binding free energy of Pep4
Fig. 9. Docking complexes with the highest binding free energy of Pep4M toto the binding site. This fact, prompted us to do ﬂexible docking
experiments in order to model in a more realistic way the binding
of the peptides against elastase.
The Pep4 and Pep4M lowest energy structures were docked
(using a fully ﬂexiblemodel of the peptides) towards the active cen-
tre of elastase (PPE, Figs. 8 and 9). The fully ﬂexible docking exper-
iments show that, both peptides display an extended conformation
along the crevice formed between the two elastase domains
(Figs. 8a and 9a). In contrast the phosphorylated form of Pep4 and
Pep4M peptides adopt a hairpin conformation and these structures
are conﬁned to the elastase active centre region (Figs. 8b and 9b).
The posttranslational modiﬁcation (phosphorylation) of the threo-
nine residue in Pep4 and Pep4M induces the formation of a large
bent conformation, mainly due to electrostatic and inter-residue
interactions (Fig. 10). In Pep4(P), the phosphothreonine Thr(P)7 is
able to establish electrostatic interactions with the guanidinium
group of Arg2 and the NHe group of Lys1 (Fig. 10a) and hydrogen
bonds with the amine group of Lys1 (Fig. 10b). In Pep4M(P), the
phosphate group of Thr(P)7 establish electrostatic interactionswith
the positively charged residue Arg2 (Fig. 10d). Additionally, in this
peptide it is also possible to observe hydrogen bonds between alter-
nate residues, such as Thr(P)7-Gly9 and Asp6-Met8 (Fig. 10c). Dif-
ferential binding energies were registered for the peptides Pep4
and Pep4M phosphorylated and non-phosphorylated when docked
to PPE (Table 2). Thus, the inter-residue interactions prompted by
the phosphorylated residue Thr(P)7, decreases the peptide-enzyme
interactions. This is in accordancewith previous studies [20], which
reported a decrease in the inhibitory activity of peptides Pep4 andto PPE, in the non-phosphorylated (a) and phosphorylated (b) form.
PPE, with the peptide non-phosphorylated (a) and phosphorylated (b).
Fig. 10. Representation of the main intramolecular electrostatic interactions and hydrogen bonds established within phosphorylated amino acid residues of Pep4 (a and b)
and Pep4M (c and d).
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the non-phosphorylated form.
Regarding to PepBBI, a Bowman-Birk inhibitor based peptide, a
distinct inhibitory behaviour relatively to PPE is also evident, when
it is in the phosphorylated and non-phosphorylated form (unpub-
lished data). Contrarily to the previous peptides, PepBBI possess
three potential phosphorylation sites: Thr3; Ser5 and Tyr11. How-
ever, as the protein kinase used to perform the phosphorylation of
the current peptide was a serine/threonine kinase (Casein Kinase
Id), it is thus expected that the phosphorylation only occurs at
the Thr3, Ser5 or at both residues (Fig. 11). Similarly to Pep4 and
Pep4M, PepBBI displays an extended conformation in between
the two domains of elastase (Fig. 11a). Considering that the phos-
phorylation only occurs at Thr3 residue, PepBBI adopts the shape of
a large loop, with the phosphate group pointing out of the struc-
ture (Fig. 11b). This structural modiﬁcation is prompted by electro-
static interactions and hydrogen bonds between the
phosphothreonine residue Thr(P)3 and the side chain of His57 at
the catalytic triad of elastase (Fig. 12a). Additionally, also occur
hydrogen bonds are formed between the phosphate group of
Thr(P)3 and Asp60 residue of the protease (Fig. 12a). These interac-
tions may reduce the activity of elastase, although to a less extentthan that registered in the non-phosphorylated version of the pep-
tide. If the phosphorylation took place at Ser5 residue, this process
does not induce any relevant structural differences relatively to the
non-phosphorylate peptide (Fig. 11a and c). This is reﬂected in the
binding energy for the peptide-enzyme interaction that remains
unaltered, whether the PepBBI is phosphorylated (7.1 kcal/mol)
or non-phosphorylated (7.0 kcal/mol, Table 2). Thus, these data
do not corroborate the experimental data that stress distinct inhib-
itory capacity for the phosphorylated and non-phosphorylated ver-
sions of the peptide. Therefore, it is not expected that the
phosphorylation of PepBBI occurs at Ser5 residue. The third option,
in which both residues might be phosphorylated, the peptide
maintains an extended conformation having both phosphate
groups inserted in the elastase active site (Fig 11d). According to
literature, it is possible to phosphorylate alternated residues, even
if small amino acid residues such as alanine or glycine occur in be-
tween them [42], and also adjacent residues [43,44]. The phos-
phate group of the phosphothreonine establish hydrogen bonds
with hydroxyl group of Ser195 at elastase catalytic triad
(Fig. 12b). Similarly to the ﬁrst option of phosphorylation site
(Thr(P)3), this interaction may cause an impediment to the normal
elastase activity and consequently a decrease in its activity.
Fig. 11. Docking of PepBBI to PPE in the non-phosphorylated form (a), phosphorylated form with a phosphothreonine residue (b), phosphoserine residue (c) and with both
phosphoresidues (d).
Fig. 12. Identiﬁcation of electrostatic interactions and hydrogen bonds between the phosphothreonine residue of PepBBI and the protease (PPE) residues His57 and Asp60 (a)
and Ser195 (b).
1364 S.C. Barros et al. / Reactive & Functional Polymers 73 (2013) 1357–1365Nevertheless, this reduction in elastase activity is less pronounced
than in the non-phosphorylated version of the peptide, according
to the experimental data obtained for the phosphorylation of Pep-
BBI in solution (unpublished data).
Therefore, considering the three possibilities of potential
phosphorylation sites in PepBBI, the options that mostly corrob-
orates with the experimental data is the ﬁrst and third option,
in which the phosphorylation occurs at Thr3 or at Thr3 and
Ser5 residue simultaneously. Although, serine residues rather
than threonine residues appeared to be more preferred phos-
phorylation targets [43,45,46], in this case the opposite seemed
to occur.Hence, the phosphorylation in Pep4 and Pep4M occur at the
phosphoresidue Thr7 and in PepBBI all evidences point out to the
phosphorylation occurring at the phosphoresidue Thr3 or Thr3
and Ser5 jointly. The phosphorylation of these residues in all the
three peptides induced a conformation alteration (formation of a
large loop, except when in presence of a pair of phosphoresidues),
similar to what has been reported in other peptides [47,48].
4. Conclusions
The combined approach of two-dimensional NMR and molecu-
lar docking techniques allowed the detection of differential
S.C. Barros et al. / Reactive & Functional Polymers 73 (2013) 1357–1365 1365conformations adopted by the tridecameric (Pep4 and Pep4M) and
undecameric (PepBBI) peptides in the phosphorylated and non-
phosphorylated form. This distinct conformation acquired by the
three peptides, is compatible with the differential inhibitory activ-
ity observed for these peptides towards elastase (PPE) in previous
studies [20].
The 2D-NMR structural studies on the peptides Pep4, Pep4M
and PepBBI, revealed signiﬁcant structural ﬂexibility in all the pep-
tides, when present in solution. Nevertheless, the ﬁnal set of 20 en-
ergy-minimised conformers obtained for these peptides revealed a
good backbone overlay, especially in the case of Pep4M where the
presence of several medium range interactions (1 < |i  j| 6 4),
indicate lower conformational mobility of the peptide in solution.
The molecular docking studies demonstrated the distinct con-
formations acquired by these peptides when their potential phos-
phorylation sites (threonine) carry or not a phosphate group in
their structure. Additionally, these studies also highlighted the in-
ter-residue and inter-molecular interactions (electrostatic interac-
tions and hydrogen bonds) that prompted these structural
modiﬁcations. The differences between the solution and docked
structures show that these peptides behave as the very important
class of intrinsically disordered proteins, which only assume the
active conformation upon meeting their physiological partners.
Phosphorylation process seemed to play a determinant role in
the structure and in the biological properties of the three peptides
included in this study. These results are important for the incorpo-
ration and choice of these peptides for wound dressings described
in other works of our group [20,21,49–51].
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